Moss, 18.06.2021

Gentian Diagnostics ASA, is a fast-growing developer and manufacturer of
innovative and efficient diagnostics for better treatment decisions. In an
updated investor presentation, the company outlines the market potential and
roadmap for its portfolio of high-impact diagnostic tests and an ambition to
generate an estimated annual revenue of NOK 1 billion in 5-7 years.
   
The growing diagnostics market puts increasing pressure on clinical laboratory
efficiency, however many of the existing, clinically relevant biomarkers are
available only on slow and inefficient platforms. Gentian's solution is to
utilize PETIA (particle-enhanced turbidimetric immunoassays), based on
proprietary nanoparticle technology and knowhow, to convert existing biomarkers
to the most efficient automated, high-throughput analysers.

"Our products offer multiple high-value benefits for clinical laboratories and
hold great value potential. Firstly, we contribute to early disease detection
and faster availability of clinically relevant information, which lead to better
treatment decisions. Secondly, we significantly improve laboratory productivity
and cost-efficiency by leveraging PETIA technology, which enable 3-10x higher
throughput than traditional immunoassay platforms," says Hilja Ibert, CEO of
Gentian Diagnostics.

Gentian's portfolio of diagnostic tests targets several large and growing
disease areas such as infections and inflammation, kidney failure and congestive
heart failure. The company has four established products, one product in market
development, and two products in development with launches scheduled for Q4 2021
and Q1 2022, respectively. Gentian also has three undisclosed biomarkers in
exploration and 'proof of concept' phases. In 2017-2020, the four established
products contributed to 31% annual revenue growth. Gentian reported NOK 79
million in revenue in 2020, up 32% from 2019.

The company's roadmap for long-term growth and value creation is founded on six
strategic pillars:

1.	Grow annual revenue from the company's four established products - Cystatin
C, fCAL, Canine CRP and fPELA - by expanding market access through additional
commercial partners and regulatory approvals
2.	Prove clinical relevance of GCAL for sepsis and COVID-19 
3.	Launch one new product per year